# Study of Deferasirox in Iron Overload From Beta-thalassemia Unable to be Treated With Deferoxamine or Chronic Anemias

> **NCT00061763** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 175 (actual)

## Conditions studied

- Beta-thalassemia
- Myelodysplastic Syndromes
- Fanconi Syndrome
- Anemia, Diamond-Blackfan
- Anemia, Aplastic

## Interventions

- **DRUG:** Deferasirox

## Key facts

- **NCT ID:** NCT00061763
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-05
- **Primary completion:** 2004-11
- **Final completion:** —
- **Target enrollment:** 175 (ACTUAL)
- **Last updated:** 2017-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00061763

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00061763, "Study of Deferasirox in Iron Overload From Beta-thalassemia Unable to be Treated With Deferoxamine or Chronic Anemias". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00061763. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*